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OBJECTIVES: Chronic Myeloid Leukemia (CML) is a myeloproliferative disease as-
sociated with a chromosomal translocation (Philadelphia chromosome). Since
2003 life-long treatment by Tyrosine Kinase Inhibitors (TKIs) have dramatically
improved survival. The objective of this study was to predict the characteristics of
the population under TKI treatment at the horizon 2015. METHODS: An epidemi-
ological model was developed over the period 2003-2015 on first and following line
therapies, combining demographic, incidence, prevalence, survival data and prob-
ability of resistance or intolerance in each line. Data were derived from published
randomized clinical studies. The model was tested over the period 2003-2009 by
comparison with retrospective market data and then extrapolated to the period
2010-2015. RESULTS: At the time of the first TKI launch (imatinib) in 2003, a prev-
alent group of 1,878 patients started treatment. Second-generation TKIs dasatinib
and nilotinib were then made available in France between November 2007 and May
2008 as second line therapy, and potentially in mid-2011 as first line. Despite a
stable annual number of 600 incident cases (1.25 x10-5) of CML eligible for a TKI first
line treatment, the total number of patients under treatment increased to 7260 in
2010 (a 3.9-fold increase since 2003) of which 1083 were in second line (15%). The
extrapolation model predicted a total of 10,069 treated patients in 2015 of which
1,618 in second line (16%) representing a 39% 5-year increase. CONCLUSIONS: The
dramatic overall survival benefit associated with TKIs was a key factor for explain-
ing the growth of the CML treated population aside from the emergence of second
line therapies.
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FOLLOWING DIAGNOSIS PER PATIENT IN RUSSIAN FEDERATION
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OBJECTIVES: With 75,880 patients under medical supervision in 2007, prostate
cancer is the fourth most frequent cancer in Russia and the first in terms of in-
crease of mortality (21,6%) with ,8909 deaths/year. Moreover metastatic prostate
cancer (MPCa) holds more than 60% of these patients at the same time being the
leading expenditure driver. The purpose of this study was to evaluate the burden of
illness and total per patient costs, associated with managing patients with (MPCa)
in the 12 months following diagnosis in Russia from perspective of public health-
care system. METHODS: A costing model combined the data of official algorithms
(standard of treatment approved by Ministry of Health) and guidelines of MPCa
management, as well as local experts opinion and published data on resource use
and unit costs from published sources to calculate total per patient direct costs of
MPCa treatment. Direct costs of MPCa include expenses on medical services and
pharmacotherapy (cytostatics, hormones and antihormones, accompanying and
other drugs). As initial treatment following diagnosis radiotherapy was used most
frequently. Use of chemotherapy was low. Relapse and mortality were not factored
into the model. Total direct medical costs of initial treatments following diagnosis
per patient were calculated for MPCa in 12 months timeframe. RESULTS: Total per
patient direct costs following diagnosis was 810,529 roubles. Analysis of the costs
structure showed that hormone therapy represents a significant higher cost to
surgery, while radiotherapy had the highest cost proportion. Pharmacotherapy
was the major driver of MPCa treatment cost (more than 50% share from all
expenditures). CONCLUSIONS: In this study quantifying the cost of MPCa treat-
ment in Russia was found a significant resource utilization and healthcare costs,
along with the major cost drivers. Given the number of new cases diagnosed in
Russian Federation, these estimates suggest a large total spending on the disease.
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OBJECTIVES: In 2008, the annual medical expenditure on cancer treatment in Japan
was approximately 16 trillion yen. In the past decade, a few molecular-targeted
drugs (MTDs) were developed for the treatment of HER2metastatic breast cancer
(HER2-MBC). The number of MTD-treated patients increases every year, which is a
concern with regard to the economic impact of cancer therapy. Trastuzumab is the
most popular alternative to HER2-MBC therapy in Japan, but it has a high national
health insurance price of approximately 220,000 yen per month for women weigh-
ing 50 kg. To estimate the clinical and economic burden of breast cancer (BC) and
HER2-MBC therapies, we commenced a large clinical database survey, by examin-
ing the diagnosis procedure combination (DPC)–based claims, which included flat
payment schemes. METHODS: The database, which consists of 15 DPC-targeted
institutions that had contracted with Medical Data Vision Ltd., includes approxi-
mately 400,000 patients. To extract the pertinent population and estimate the clin-
ical and economic burden of MTDs, a target population consisting of individuals
diagnosed with BC on or before March 31, 2010, aged more than 20 years, and
treated with MTDs for HER2-MBC was chosen. The observation period was April 1,
2008 to March 31, 2010. RESULTS: During the observation period, 2,419 individuals
were diagnosed with BC. Of these, 98 were receiving or had received MTDs. The
observed estimated economic cost of BC treatment was 994,000 yen, with an ob-
servation duration of approximately 14.0 person-months. The cost of HER2-MBC
treatment with MTDs was estimated at 4,455,000 yen with a duration of 17.4 per-
son-months. CONCLUSION: HER2-MBC therapy seriously impacted the annual
medical expenditure in Japan and had a rare survival duration. The database was
useful for conducting an economic analysis of cancer treatment in Japan.
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OBJECTIVES: To estimate direct medical costs of Tuberous Sclerosis Complex with
neurological and developmental manifestations under the Brazilian public health
care system perspective (SUS). METHODS: A retrospective database analysis was
developed from ICD-10 search from January/2008 (revision of table of procedures by
SUS Information Technology Department/DATASUS) to February/2011. Neurolog-
ical and developmental manifestations of TSC included in the study were sub-
ependymal giant cell astrocytoma (SEGA), epilepsy, epileptic syndromes/infantile
spasm, mental disability and autism, based on prevalences and expected costs to
SUS. Direct medical costs per patient per year for each manifestation were esti-
mated based on DATASUS ambulatory (high complexity) and hospital settings,
whose databases included 2,016,188 and 9,236,360 persons, respectively. Epidemi-
ologic literature was applied to correct misreported data and estimate average cost
per patient per year for all manifestations. Sensitivity analysis was performed for
the prevalence of manifestations. Costs were reported in 2010 Reals. RESULTS: The
most prevalent procedure (and respective unit cost) for SEGA, epilepsy/epileptic
syndromes/infantile spasm, and mental disability/autism were surgery (R$6302),
hospitalization for uncontrolled seizure (R$585) and anti-epileptic drugs (R$1887),
and psychiatric ambulatory treatment (R$275/R$892), respectively. The average
direct medical costs per patient per year at SUS were R$7672 for SEGA, R$2,570 for
epilepsy, R$1,349 for epileptic syndromes/infantile spasm, R$4668 for mental dis-
ability and R$2,276 for autism. Average cost per patient per year for all manifesta-
tions was R$19,180. This cost varied from R$13,580 to R$22,556 in sensitivity anal-
ysis. TSC neurological and developmental manifestation costs are expected to be
underestimated due to lack of access and provision of health services, mainly in
long-term disorders. CONCLUSIONS: TSC neurological and developmental mani-
festations impose significant economic burden to the Brazilian public health care
system. However, the real economic burden is potentially higher as the diagnosis
and treatment of the disease and its manifestations are underestimated consider-
ing restrictions of access and health service provision.
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OBJECTIVES: To review incidence rate and burden of illness associated with Hu-
man Papillomavirus (HPV) related female genital (cervical, vulvar and vaginal) can-
cers in Spain. METHODS: Databases and registries searched for data retrieval in-
cluded EMBASE, PUBMED, Cochrane, Globocan, WHO, SEER and relevant grey
literature. Studies reporting epidemiology and costs associated with HPV-related
genital cancers in females were of interest. RESULTS: In 2008, age standardized
incidence rate of cervical cancer per 100,000 females was 6.3 in Spain compared to
5.7, 7.2, 10.6 and 15.3 in US, UK, Europe and worldwide, respectively (Globocan
2008). The incidence of cervical cancer was highest among Spanish women aged
45-54 years. Incidence rate of vulvar and vaginal cancers ranged from 1.6-4.0 and
0.3-0.7 per 100,000 females, respectively. Additionally, vulvar and vaginal cancers
were most common among older women (70 and 65 years, respectively). In the
same year (2008), mortality rate due to cervical cancer was 1.9 per 100,000 females
(WHO 2010). Mortality rate for vulvar-vaginal cancer was 9.34% from 1997-2008
(Gil-prieto 2011). Annually, 7.6 million pap smear tests were performed in Spain at
the cost of €622 million (Castellsague 2009). Average number of hospitalizations per
year was 4151 due to cervical cancer and 17,883 due to vulvar-vaginal cancers.
Mean (SD) length of hospital stay due to cervical cancer was 8.7 (15.2) days and 8 (10)
days due to vulvar-vaginal cancer (Gil 2007, Gil-prieto 2011). Estimated annual cost
of hospitalization due to cervical cancer and carcinoma in situ was €19 million (Gil
2007). Indirect costs (productivity loss) associated with mortality related to cervical
cancer were €1.1 million (Oliva 2006). CONCLUSIONS: HPV-related genital cancers
have significant incidence and mortality rate in Spanish women with higher risk in
elderly female population. The direct and indirect costs incurred due to genital
cancers are substantial and reflect considerable economic burden.
PCN50
FIRST AND SECOND LINE LUNG CANCER TREATMENT UTILIZATION PATTERNS
AND ASSOCIATED COSTS IN A UNITED STATES HEALTH CARE CLAIMS
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OBJECTIVES: Because treatment options for lung cancer are changing rapidly, it is
important to understand current treatment patterns and cost implications. We
conducted a retrospective claims analysis to identify common lung cancer regi-
mens and direct medical costs in a large US commercial health insurance and
Medicare Advantage database. METHODS: We identified patients with lung cancer
receiving 1st or 2nd line chemotherapy between January 2006 to December 2010
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using an algorithm utilizing enrolment records and ICD-9 codes. A patient flow
algorithm was constructed to define treatment cohorts. Patients were stratified
based on the lung cancer drug treatment received following diagnosis and first line
therapy. Total costs are report for the 1 year follow up period after initiation of drug
treatment. RESULTS: A total of 2739 lung cancer patients were included in the
analysis; 53% 65 yr. Paclitaxel or docetaxel plus platinum were the most com-
monly utilized 1st line regimens. Pemetrexed plus docetaxel was the most com-
mon 2nd line treatment. Among patients receiving 1st line treatment and remain-
ing enrolled in the health plan, only 16.7% received 2nd line treatment. Total costs
(average / SD) in the year following chemotherapy initiation was $70,205 
66,956 (range $50,000-$120,000) for those with 1 line of therapy versus $93,432
$66,208 (range $62,000-$169,000) with two or more lines. For all patients, average
ambulatory care costs (which included IV administration costs) were
$34,44940,847, intravenous drug costs ($17,246 27,488), and inpatient hospital
costs (14,180 $31,409) comprised the largest proportion of costs in the year fol-
lowing chemotherapy initiation. CONCLUSIONS: In this analysis, few lung cancer
patients received 2nd line treatment.. For those patients who received 2nd line
treatment and beyond, direct medical care costs are over $23,000 higher over years
2006-10 compared to those receiving only one line. Ambulatory costs comprised
the greatest proportion of total costs (50%).
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INSURED PATIENTS WITH METASTATIC BREAST CANCER IN THE UNITED
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OBJECTIVES: To compare health care resource utilization (HRU) and costs by line of
therapy (LOT) among patients with metastatic breast cancer (MBC). METHODS:
MarketScan® databases, January 1, 2005 to December 31, 2009, were used to iden-
tify women aged 18 with breast cancer (ICD-9-CM of 174.xx). The index date was
the first prescription fill or administration of anti-neoplastic agents. Either a 90-day
gap in treatment or initiation of a new regimen ended each LOT. Per patient per
month (PPPM) expenditures for utilizers of inpatient (IP), outpatient (OP), emer-
gency department visits (ED), MBC-drugs (oral and infused), hormonal, radiology,
and supportive therapies across four LOTs (1L-first line, 2L-second, 3L-third, 4L-
fourth) were statistically compared. HRU rates (Visits per patient with 1 Visit)
were also compared. RESULTS: A total of 8494 MBC patients (1L:7,765; 2L:4,077;
3L:2,033, 4L:1,059) were included. Bone metastases were most common (43.9%) at
index followed by liver (17.7%) and lung (12.8%). PPPM expenditures for IP (1L:
$1,183, 2L:$1,318, 3L: $1,401, 4L:$1,670; p0.660), OP (1L:$1,751, 2L:$1,624; 3L: $1,626;
4L:$1,626, p0.413), and ED (1L:$64, 2L:$67, 3L: $73, 4L:$57 p0.997) were not stas-
tically siginificantly different across the four LOTs. PPPM expenditures for MBC
oral-drugs (1L:$460, 2L:$530, 3L:$589, 4L:$743,p0.37), hormonal (1L:$87 , 2L:$65, 3L:
$70, and 4L:$55,p0.388), and radiology therapies (1L:$290,2L:$280,3L: $280,and 4L:
$271, p0.999) were also not statistically different across LOTs. MBC infused-drugs
(1L:$4096,2L:$4,607,3L:$4,841, 4L:$4,521,p0.001) did differ. Within supportives,
PPPM across LOTs were stastically different for anti-emetics (1L:$283,2L:$321;3L:
$320;4L:$311,p0.007) and pain medications (1L:$42,2L:$50;3L:$62;4L:$71,p0.002)
but not for IV-bisphosphonates (1L:$406,2L:$412;3L:$419;4L:$410,p0.964). The
mean HRU rates for IP (range1.4-1.4), ED (1.7-1.8), OP hospial (8.4-9.4) office-visit
(11.2-12.6), and Other outpatient visits (18.9-20.5,) were similar across LOTs.
CONCLUSIONS: No significant variation in the PPPM costs of (IP, OP, ED, MBC oral
drugs, hormonal, radiology, or IV bisphosphonates) was oberved across four LOTs.
LOT costs differed for infused drugs, anti-emetics, and pain medication within this
MBC population. Further research is required to explore these variations.
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AMONG PATIENTS DIAGNOSED WITH ADVANCED MELANOMA IN THE UK,
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SURVEY (MELODY STUDY)
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OBJECTIVES: To describe patterns of health care resource utilisation and associ-
ated costs for patients with advanced melanoma in the UK, Italy, and France.
METHODS: For patients receiving systemic treatment, or supportive care, hospi-
talisation, hospice care, and outpatient data were retrieved retrospectively from
advanced disease diagnosis until 1 May 2008 as part of a multicountry observa-
tional study (MELODY; Lorigan et al., ISPOR 2010). Costs were estimated by multi-
plying the utilisation level by unit cost. In an exploratory analysis, costs were
compared between individuals who died within one year of initiating first-line
treatment (short-term survivors) and those with 1 year follow-up (long-term
survivors). RESULTS: Hospitalisation costs were highest in France (€6262 per-per-
son compared with €3225 in the UK and €2486 in Italy), reflecting higher rates of
hospitalisation. In contrast, outpatient costs were highest in the UK (€782 per-
person, compared with €115 in France and €72 in Italy), reflecting both the highest
rate and frequency of outpatient visits and the highest cost per visit. While daily
hospice costs were lowest in the UK, frequency and duration of hospice care were
notably higher than in Italy or France, resulting in the highest total hospice costs
per-person. Hospitalisation rates were consistently higher during supportive care
compared with systemic therapy. It should be noted that roughly a third of patients
entered clinical trials and therefore could not be included in the analysis. In ex-
ploratory analysis, total costs were generally higher for long-term survivors, but
monthly per-patient costs were generally lower for long-term survivors, consistent
with a hypothesis that resource utilisation and costs do not necessarily increase
proportionally with extended survival. CONCLUSIONS: Total costs associated with
resource utilisation for advanced melanoma patients varied across countries.
Overall cost differences were due to differences in frequency and intensity of util-
isation patterns and variation in unit costs of health resources.
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OBJECTIVES: Data on economic burden of head & neck (H&N) and anal cancers in
Germany is scarce. Human papillomavirus (HPV) infection is likely to be responsi-
ble for 16% to 72% of H&N cancer, and 84% of anal cancer. This study aimed to
assess the annual management costs (hospitalisations, inpatient rehabilitations,
sick leaves) associated with these HPV-related cancers from the German Statutory
Health Insurance (SHI) perspective. METHODS: This study was based on the retro-
spective analysis of five German databases, which cover hospitalisations (German
Federal Statistical Office-Destatis), major categories of treatment such as surgery,
radiotherapy and medical (Institute for the Hospital Remuneration System-InEK),
inpatient rehabilitations (German Public Pension Insurance-DRV) and sick leaves
(Local-SHI-funds, Federal Ministry of Health). Associated number of cancers,
health care resource use, and costs were identified and extracted using ICD-10
codes (H&N cancer: C01-C06, C09-C14, C32; anal cancer: C21). The HPV-related
cancers total cost was estimated based on the percentage of each cancer and ana-
tomical site likely to be attributable to HPV. RESULTS: In 2008, 69,631 hospitalisa-
tions for H&N and anal cancers were reported (92% due to H&N cancer), whereas
the number of inpatient rehabilitations and sick leaves were 5,415 and 18,391,
respectively. The estimated total cost associated with HPV-related H&N and anal
cancers was €111 million, mainly represented by H&N cancer (74%). Hospitalisa-
tions, inpatient rehabilitations, and sick leaves, accounted for 82%, 4%, and 15% of
total HPV-related cost, respectively. CONCLUSIONS: The estimated annual cost of
HPV-related H&N and anal cancers contribute to a significant economic burden in
Germany, appearing to be as important as cost of HPV-related cervical cancer, and
should be considered when assessing health and economic benefits of HPV vacci-
nation in both genders. Furthermore, this cost is likely to be underestimated since
outpatient management cost is not included, and may be significant for these
cancers.
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OBJECTIVES: There are approximately 4 million of Hepatitis C Virus (HCV) carriers
in Europe. HCV infection is a leading cause of liver cirrhosis (LC), transplantation
(LT), and hepatocellular carcinoma (HCC). On the brink of new antiviral treatments
in France, we aimed at evaluating the 2009 hospital costs related to chronic hepa-
titis C.METHODS:All hospital stays with a B18.2 ICD-code were extracted from the
2009 hospital database and distributed in five groups: uncomplicated chronic hep-
atitis C, LC, HCC, LT, and unclassifiable. Costs were calculated using the French
medical information system (PMSI). RESULTS: A total of 27,258 stays were identi-
fied (15,482 patients): uncomplicated hepatitis C (42%), LC (41%), HCC (13%), LT (2%),
unclassifiable (2%). Mean length of stay was 6.1 and 28.7 days in medical and
surgical units respectively; 8,214 medical procedures for baseline/follow-up as-
sessments were carried out in patients with uncomplicated hepatitis, including
1,970 liver biopsies. Annual cost was estimated at 65,652,651€, including 47% for LC,
18% for HCC, and 19% for LT. The mean annual cost per patient increased from
1,049€ (uncomplicated hepatitis) to 4,748€ for LC, 6,513€ for HCC, and 40,152€ for LT
(expensive drugs excluded). Expensive drugs accounted for 7% of total costs in
public sector (95% of all stays), including 30% for cancer therapies, 33% for eryth-
ropoietins, 12% for anti-infection drugs and 11% for hemostasis. CONCLUSIONS:
This first analysis devoted to HCV infection of the French hospital national data-
base brings new and essential information. It shows that 84% of HCV-related hos-
pital costs are attributable to advanced liver diseases, and 19% to the 2% of patients’
recipients of a liver transplant. Together with more efficient therapies, enhancing
screening and access to treatment policy could substantially relieve the social
burden of HCV.
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OBJECTIVES: In Germany, breast cancer is the most frequent cancer. In 2007, 7.2%
of total German health care expenditure was spent on breast cancer. Despite, its
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